Tag: Biogen

Biogen to Acquire Novel Clinical Stage Asset from Pfizer

biogen
Biogen Inc. Jan. 13, 2020 announced an agreement to acquire from Pfizer Inc. PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patien...

Biogen Demonstrated Positive Results of VUMERITY Clinical Trials

Biogen Inc. announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI) tolerability of VUMERITY™ (diroximel fumarate), a new FDA-ap...

National Multiple Sclerosis Society Criticized Biogen for Vumerity Price

The National Multiple Sclerosis Society has criticized Biogen for the $88,000 yearly list price it placed on Vumerity (diroximel fumarate), the newly approved oral disease-modifying treatment (DMT) fo...

Former Biogen Sales Manager Awarded Nearly $6m in Damages

Former Biogen sales manager Danita Erickson reported a colleague's misconduct and got fired a few months later. Now, she's won nearly $6 million in damages from a jury that determined she'd been wrong...

Biogen Agreed with Samsung Bioepis on Exclusive Rights to Commercialize Two New Ophthalmology Biosim...

biogen
Biogen Inc. announced a new proposed transaction with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 r...

FDA Approved VUMERITY™ for Relapsing Forms of Multiple Sclerosis Treatment

Biogen Inc. and Alkermes plc announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treat...

Biogen Recall Avonex in the UK

Biogen Idec UK is recalling batches as a precautionary measure due to a manufacturing issue. CLDA Number CLDA (19)A/06 MDR Number MDR 57-10/19 Company name Biogen Idec UK Pr...

Treatment with SPINRAZA Resulted in Survival of 100% of Patients, Biogen Reports

biogen
Biogen Inc. announced that the journal Neuromuscular Disorders has published data from NURTURE, the first study investigating a treatment targeting the underlying cause of spinal muscular atrophy (SMA...

Eisai and Biogen Decided to Discontinue Clinical Studies on Oral BACE Inhibitor

Eisai Co., Ltd. and Biogen Inc. announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbe...

Alkermes, Biogen Announced Positive Results from Phase 3 Study of Diroximel Fumarate

biogen
Alkermes plc and Biogen Inc. announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fuma...

NICE Published Amended Draft Guidance for Spinraza

More children with the rare genetic disorder spinal muscular atrophy (SMA) can now be treated with Spinraza after on 3 July NICE published amended draft guidance following a proposal for extending t...

Biogen Completed Acquisition of Nightstar Therapeutics Worth $800m

biogen
Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retin...

Biogen published New Phase 3 Interim Results of EVOLVE-MS-1 Study

Biogen Inc. announced new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with...

NICE Granted Biogen’s Spinraza® Positive Recommendation for Funding in the UK

Biogen Inc. announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National Health Service (NHS). Th...

Biogen Said It Will Continue to Work on Alzheimer’s Despite Failed Trials

biogen
Biogen said it will continue to work on Alzheimer’s but will reduce its risk by diversifying its pipeline and approach. Biogen Inc. executives sought on Wednesday to ease investors’ concerns over t...

Biogen and Eisai Stop Trials of Alzheimer’s Treatment

Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients wi...